Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …

Bedaquiline is recommended by the World Health Organization for the treatment of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We …

Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients …

South African patients with rifampicin-resistant tuberculosis (TB) and resistance to
fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) …

Background The emergence of drug resistance is a major threat to global tuberculosis (TB)
care and control. The World Health Organization (WHO) estimates that up to half a million …

Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment
failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant …

Optimal treatment regimens for patients with extensively drug-resistant tuberculosis (XDR-
TB) remain unclear. Long-term prospective outcome data comparing XDR-TB regimens with …

Abstract Background In 2012, the Food and Drug Administration approved use of
bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis …

Rationale Bedaquiline has been classified as a group A drug for the treatment of multidrug-
resistant tuberculosis (MDR-TB) by the World Health Organization; however, globally …